Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05001516
• Other study ID #: CA128-1033
• Secondary ID: CA128-1033LM-302
• Status: Completed
• Phase: Phase 1
• Start date: December 29, 2021
• Est. completion date: January 4, 2024

Study information

• Verified date: March 2024
• Source: Turning Point Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Description:

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 4, 2024
• Est. primary completion date: January 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure;
• Aged =18 years old when sign the ICF, male or female;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose;
• Life expectancy = 3 months;
• Phase ?a (Dose Escalation): Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include but not limit to gastric and gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, pancreatic carcinoma, biliary tract carcinoma, colorectal carcinoma, ovarian carcinoma.
• Claudin18.2(CLDN18.2) status will be tested by central immunohistochemistry (IHC) testing for the enrolled subjects if the archived tumor tissue samples are available, and the enrolment is not dependent on the CLDN18.2's status.
• CLDN18.2 positive may be required for the high dose levels as determined by Safety Monitoring Committee(SMC), the subjects need to have CLDN 18.2 positive available before enrolled and dosed, and the tumor types are limited to the types listed as phase Ib (Dose expansion).
• Phase Ib (Dose Expansion): Subjects must have histological or cytological confirmation of recurrent or refractory CLDN18.2 positive* advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include the

following or the specific tumor types that are determined by SMC:

• Gastric and gastroesophageal junction adenocarcinoma;
• Pancreatic carcinoma;
• Biliary tract carcinoma;
• Colorectal carcinoma with known Microsatellite instability-high(MSI-H)/Different Mismatch Repair(dMMR);
• Esophageal adenocarcinoma;
• Ovarian mucinous carcinoma; *CLDN18.2-positive: defined as CLDN18.2 expression confirmed by central immunohistochemistry (IHC) test and with a staining intensity of 1+ to 3+ in = 10% of the tumor cell. At least 3 subjects with a staining intensity of 2+ to 3+ in = 40% of the tumor cells should be included for the dose expansion stage.
• At least one evaluable lesion (including measurable and unmeasurable) for phase Ia dose escalation, and one measurable lesion for phase Ib dose expansion, according to RECIST v1.1;
• Subjects must show appropriate organ and marrow function in laboratory examinations

within 7 days prior to the first dose:

• Bone marrow reserve: Platelet count (PLT) = 90 × 109/L; Absolute neutrophil count (ANC) = 1.5 × 109/L; Haemoglobin = 9 g/dL, without receiving Erythropoietin(EPO), G-Colony-Stimulating Factor(CSF), or Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) within 14 days and blood transfusion including red blood cell and platelet transfusion in at least 7 days prior to first dose;
• Coagulation function: International Normalized Ratio(INR) = 1.5; Activated Partial Thromboplastin Time(APTT) = 1.5 × ULN;
• Liver function: Total bilirubin = 1.5 × ULN (Subjects with Gilbert's Syndrome are allowed if total bilirubin = 3 × ULN); Aspartate Transaminase(AST) and Alanine Aminotransferase(ALT) = 2.5 × ULN without liver metastases (= 5 × ULN if liver metastases are present); Albumin = 2.5 g/dL;
• Kidney function: Serum creatinine = 1.5 × ULN, or creatinine clearance = 50 mL/min (using Cockcroft-Gault formula);
• Cardiac function: Left ventricular ejection fraction (LVEF) = 50%; QT interval (QTcF) = 480 ms;
• Subjects who are able to communicate we

Exclusion Criteria:

• Exposure to any IMP, or participate in any other clinical trial within 21 days prior to 1st dosing of LM-302;
• Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-302, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy,

etc. Following treatments have different time limits:

• Local small-scale palliative radiotherapy (bone metastasis radiotherapy to control pain) within 14 days prior to 1st dosing;
• Oral anti-tumor therapy, including fluorouracil antitumor drugs and small molecular targeted drugs, etc. within 14 days or 5 half-life of the drug (whichever is shorter) prior to 1st dosing;
• Traditional Chinese medicine with anti-tumor indication within 14 days prior to 1st dosing.
• Nitrosourea or Mitomycin C within 42 days prior to 1st dosing.
• Any adverse event from prior anti-tumor therapy has not yet recovered to = grade 1 of CTCAE v5.0 (Except for toxicities without safety risk judged by the investigator, such as alopecia, and other = grade 2 long term toxicities);
• Pre-existing peripheral sensory or motor neuropathy = Grade 2;
• Subjects with uncontrolled tumor-related pain. Subjects requiring analgesic treatment must be on a stable regimen before participating in the study. Symptomatic lesions amenable by palliative radiotherapy (e.g., bone metastases or metastases causing nerve damage) should be treated prior to enrolment. For the asymptomatic metastatic lesions whose further growth would likely cause functional defects or intractable pain, if appropriate, local treatment should be considered before enrolment;
• Subjects with known central nervous system (CNS) or meningeal metastasis;
• Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;
• Subjects who are allergic or hypersensitive to LM-302 (The excipients are L-Glutamic acid, L-Arginine, Trehalose dihydrate and polysorbate 80 (for injection)) or similar products;
• Subjects who have received the treatment targeting to CLDN18.2 or Monomethyl

Auristatin E(MMAE) based Antibody-Drug Conjugates (ADCs):

• Subjects who have received the treatment with ADCs targeting to CLDN18.2 are not eligible;
• Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible, but can be enrolled if they were tolerable to the treatments and have experienced a 28-day's washout period prior to 1st dosing of LM-302;
• For Phase Ib (Dose Expansion), subjects who were not response to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible;
• Administrate strong inhibitors/strong inducers of CYP3A4 within 14 days prior to 1st dosing of LM-302;
• Subjects with known active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.
• Use of any live vaccines (e.g., against infectious diseases such as influenza, varicella, COVID-19, etc.) within 28 days prior to 1st dosing of LM-302;
• Subjects with the history of interstitial lung disease or drug-induced interstitial lung disease/pneumonitis;
• Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists (except for preventive treatment at a stable dose);
• Subjects with gastric outlet obstruction, persistent recurrent vomiting or uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st dosing of LM-302;
• Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-302 (excluding tumor biopsy, puncture, etc.);
• Subjects who have other active malignancies which are likely to require the treatment;
• Subjects who have severe cardiovascular disease, including but not limited to:
• Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, and II-III degree atrioventricular block, etc.;
• Thromboembolic events requiring therapeutic anticoagulation, or equipped with venous filters;
• Cardiac insufficiency of grade III~IV according to the New York Heart Association (NYHA) standards;
• Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months prior to 1st dosing of LM-302;
• Clinically uncontrollable hypertension;
• Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection (e.g., active Corona Virus Disease 2019(COVID-19)/Severe Acute Respiratory Syndromes(SARS)-COVID-2 infection, etc.) requiring antibiotics and/or other therapeutic administration, while SARS-COVID-2 testing is not mandatory for study entry, and the testing should follow local clinical practice guidelines/standards.
• Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;
• HIV infection, active Hepatitis B Virus(HBV) and Hepatitis C Virus(HCV)infection, with

the exception:

• Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-hepatitis B core(HBc)] and absence of HBsAg), as well as with normal liver function are eligible. Otherwise, if HBV infection was indicated, those with HBV DNA < 500 IU/ML (or equivalent level) and normal liver function, combined with clinical manifestations, judged by the investigator to exclude active infection can be enrolled;
• Subjects with positive HCV antibody but negative hepatitis C virus RNA test results and normal liver function are eligible.
• Child-bearing potential female who have positive results in pregnancy test or are lactating;
• Subjects who have psychiatric illness or disorders that may preclude study compliance;
• Subject who is judged as not eligible to participate in this study by the investigator.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• LM-302
All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

Locations

Country	Name	City	State
United States	Local Institution - 0013	Duarte	California
United States	Local Institution - 0017	Fullerton	California
United States	Local Institution - 0015	Houston	Texas
United States	Local Institution - 0012	Lafayette	Indiana
United States	Local Institution - 0018	New York	New York
United States	Local Institution - 0016	Oklahoma City	Oklahoma
United States	Local Institution - 0020	Paramus	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Turning Point Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To explore the correlation between CLDN18.2 expression and anti-tumor activity of LM-302	Test CLDN18.2 expression and anti-tumor activity of LM-302	Up to 2 years
Primary	Dose limiting toxicity (DLT)	DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period	Cycle 1 of each cohort. Duration of one cycle is 21 days
Primary	Number of participants with adverse events and serious adverse events	The safety profile of LM302 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	From the first administration in Cycle 1 date 1(C1D1)up to 1 year
Primary	Change in Vital Signs-ear temperature	Change in vital signs-ear temperature will be measured after the subject has been fully rested	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Vital Signs-pulse rate	Change in vital signs-pluse rate will be measured after the subject has been fully rested.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Vital Signs-systolic pressure	Change in vital signs-systolic pressure will be measured after the subject has been fully rested.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Vital Signs-diastolic blood pressure	Change in vital signs-diastolic blood pressure will be measured after the subject has been fully rested.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Physical examination-weight	Change in Physical examination-weight will be measured with only light clothes	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Incidence of Abnormal Clinical Laboratory Test Results-hematology	Number of participants with incidence of abnormal clinical lab test results like hematology will be assessed.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Incidence of Abnormal Clinical Laboratory Test Results-Biochemistry	Number of participants with incidence of abnormal clinical lab test results like Biochemistry will be assessed	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Incidence of Abnormal Clinical Laboratory Test Results-Urinalysis	Number of participants with incidence of abnormal clinical lab test results like Urinalysis will be assessed.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Incidence of Abnormal Clinical Laboratory Test Results-Coagulation test	Number of participants with incidence of abnormal clinical lab test results like Coagulation test will be assessed	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Electrocardiogram (ECG)-(R wave)RR interval	RR interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once. RR is the standard heart rate which calculated by 60 divided by heart rate.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Electrocardiogram (ECG)-QT interval	QT interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.	Baseline C1D1through approximately 1 year after first administration of LM302
Primary	Change in Electrocardiogram (ECG)-QRS duration	QRS duration of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.	Baseline C1D1through approximately 1 year after first administration of LM302
Secondary	Area under the serum concentration versus time curve within one dosing interval (AUCtau)	Blood samples will be collected at time points of 0 h, immediately after infusion stop, as well as at 1 h,4 h, 8 h, 24 h, 48 h (Day 3), 168 h (Day 8), and 336 h (Day 15) after infusion stop in cycle 1 and cycle 4; 0 h in cycle 2, cycle 3 and cycle 5; pre-dose (0 h) will be collected in every other cycle for the subsequent cycles. i.e., in cycle 6, cycle 8, … etc.; at EOT/early withdraw from the study (if the EOT/early withdraw occur when PK blood sampling isn't stipulated). The timepoints of PK sample may be adjusted base on the human PK data. The blood samples for PK analysis will be collected as much as possible if the subjects end of treatment/early withdraw.	Up to 1 year
Secondary	Volume of distribution at steady state (Vss)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Maximum serum concentration (Cmax)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Minimum serum concentration(Cmin)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Time to reach maximum serum concentration (Tmax)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Clearance (CL)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Terminal half-life (T1/2)	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Dose proportionality	To determine the pharmacokinetics (PK) profile of LM302	Up to 1 year
Secondary	Objective response rate of LM-302.	Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: objective response rate (ORR, complete response(CR)+ partial response(PR))	Up to 1 year
Secondary	Duration of response of LM-302.	Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: Duration of response (DOR)	Up to 1 year
Secondary	Disease control rate of LM-302.	Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: disease control rate (DCR, CR+PR+SD)	Up to 1 year
Secondary	Progression-free survival of LM-302.	Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator:progression-free survival (PFS)	Up to 1 year
Secondary	To assess the immunogenicity of LM-302;	Blood samples collected for Anti-Drug Antibody(ADA) assessment will be performed at 0 h of Day 1 (within 30 min prior to infusion) in cycle 1 to Cycle 5; 0 h of Day 1 in every other cycle (within 30 min prior to infusion) for the subsequent cycles, i.e., in cycle 6, cycle 8, … etc., the EOT/early withdraw from the study and safety follow-up. Nab will be detected if necessary.	Up to 1 year

External Links

•   BMS Clinical Trial Information
•   BMS Clinical Trial Patient Recruiting